RxDoctor Payments DataLook up a doctor →

Jeffrey Richmond

Psychiatry · Denver, CONPI 1831414507

Payments from drug & device makers

$424,168in general payments, 2019–2025

Across 1,055 payments — averaging $402.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$127K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108K
  • Idorsia Pharmaceuticals US Inc$69K
  • Axsome Therapeutics, Inc.$55K
  • AbbVie$33K
  • E.r. Squibb & Sons, L.L.C.$13K
  • plus $18K from 28 others

What the payments were for

  • Consulting fees$33,7958%
  • Speaking & faculty fees$329,23578%
  • Travel & lodging$40,75210%
  • Food & beverage$20,2645%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$424,168 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.

See all psychiatry providers in Colorado

Medicare billing

Part B allowed, 2024
$186,926
Medicare patients
29
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$62,503
CaplytaLumateperone Tosylate16$26,639
LybalviOlanzapine/Samidorphan Malate15$24,228
TrintellixVortioxetine Hydrobromide18$21,226
AuvelityDextromethorphan Hbr/Bupropion22$17,219
BelsomraSuvorexant14$6,279
Bupropion XlBupropion Hcl42$1,435
Fluvoxamine Maleate11$1,376
Methylphenidate ErMethylphenidate Hcl13$1,237
Clonazepam89$1,107
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$859
Venlafaxine Hcl ErVenlafaxine Hcl26$857
Lamotrigine49$760
Trazodone Hcl55$746
Mirtazapine29$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$6,915$62,50313 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$108,100$26,63916 claims
Alkermes, Inc.Lybalvi$480$24,22815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$438$21,22618 claims
Axsome Therapeutics, Inc.Auvelity$55,475$17,21922 claims
MerckBelsomra$24$6,27914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.

Other psychiatry in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →